Cargando…
Design and rationale of a randomized control trial testing the effectiveness of combined therapy with STAtin plus FENOfibrate and statin alone in non-diabetic, combined dyslipidemia patients with non-intervened intermediate coronary artery disease - STAFENO study
BACKGROUND: Despite the chronicled success of low-density lipoprotein cholesterol (LDLc)-lowering statin therapy, substantial residual cardiovascular (CV) disease risk remains a problem worldwide, highlighting the need to for combination therapies targeting non-LDLc factors, such as with fenofibrate...
Autores principales: | Kwon, Taek-Geun, Jang, Albert Youngwoo, Kim, Sang Wook, Hong, Young Joon, Bae, Jang-Ho, Lee, Sung Yun, Kim, Sang-Hyun, Han, Seung Hwan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178941/ https://www.ncbi.nlm.nih.gov/pubmed/32321551 http://dx.doi.org/10.1186/s13063-020-04291-5 |
Ejemplares similares
-
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010) -
Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
por: Alagona, Peter
Publicado: (2010) -
The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia
por: Bays, Harold E., et al.
Publicado: (2010) -
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022) -
A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination
por: Filippatos, Theodosios D.
Publicado: (2012)